December 11, 2018
Pfizer Japan launched a biosimilar version of the major rheumatoid arthritis (RA) drug Remicade (infliximab) on December 10, marking the company’s entry into the Japanese follow-on biologics market. The product, which joined the NHI price list in late November, is...read more